- Home
- LYEL
as 11-26-2025 3:14pm EST
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 369.4M | IPO Year: | 2021 |
| Target Price: | $16.67 | AVG Volume (30 days): | 33.9K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -21.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.65 - $24.80 | Next Earning Date: | 11-12-2025 |
| Revenue: | $41,000 | Revenue Growth: | -34.92% |
| Revenue Growth (this year): | -82.44% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Lyell Immunopharma Inc. (LYEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hill Stephen J. | LYEL | Chief Operating Officer | Nov 10 '25 | Sell | $16.12 | 95 | $1,531.40 | 15,750 | |
| Seely Lynn | LYEL | President and CEO | Nov 10 '25 | Sell | $16.11 | 412 | $6,637.32 | 67,159 | |
| Lee Gary K. | LYEL | Chief Scientific Officer | Nov 10 '25 | Sell | $16.16 | 138 | $2,230.08 | 15,366 | |
| Bulis Veronica Sanchez | LYEL | VP, Corporate Controller | Nov 10 '25 | Sell | $16.10 | 239 | $3,847.90 | 9,213 |
Latest Lyell Immunopharma Inc. News
LYEL Breaking Stock News: Dive into LYEL Ticker-Specific Updates for Smart Investing
Associated Press Finance
14 days ago
Lyell Immunopharma: Q3 Earnings Snapshot
GlobeNewswire
14 days ago
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
BioPharma Dive
15 days ago
Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data
Pharmaceutical Technology
15 days ago
Lyell acquires worldwide rights from ICT to CAR T-cell therapy
MT Newswires
16 days ago
Lyell Immunopharma Acquires Global Rights to CAR T-Cell Product Candidate for Colorectal Cancer
GlobeNewswire
17 days ago
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
GlobeNewswire
23 days ago
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
GlobeNewswire
5 months ago
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
Compare LYEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LYEL Lyell Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.